Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments

Gillham, R. A.; Baker, Gus A.; Thompson, Pamela J.; Birbeck, K.; McGuire, Anthony; Tomlinson, Laura; Eckersley, L.; Silveira, C.; Brown, Sandra T.

doi:10.1016/0920-1211(95)00102-6

Cited by 75 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The SEALS is a patient-rating questionnaire designed to measure the effects of antiepileptic treatment on aspects of healthrelated quality of life ( I 6). The revised version of the SEALS used in this study has demonstrated the ability to discriminate between patients receiving single or combination AED therapy (17). The SEALS was used to assess the impact of side effects and symptoms associated with health-related quality of life.…”

Section: Methodsmentioning

confidence: 99%

Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin

et al. 1999

View full text Add to dashboard Cite

Summary: Purpose: Lamotrigine is an effective add-on therapy against a range of epileptic seizure types. Comparative studies with carbainaLepine (CBZ) as monotherapy in newly diagnosed epilepsy suggest similar efficacy. In this study, lamotrigine (LTG) and phenytoin (PHT) are compared.Methods: In a double-blind parallel-groups study. I X 1 patients with newly diagnosed untreated partial seizures or secondarily or primary generalised tonic-clonic seizures were randoniised to two treatment groups. One group (n = 86) received LTG titrated over 6 weeks from a starting dose of 100 mg/day. The other (ti = 95) received PHT titrated from 200 ing/tlay. Treatment continued for 5 4 8 weeks. K i~s i d t x ;The percentages of patients remaining on each treatment and seiLure frec during the last 24 and 40 weeks of the study, and times to first seizure after the first 6 weeks of treatment (dose-titration period). did not differ significantly between the treatment groups. These were measures of efficacy. Time to discontinuation, a composite index of effi safety, likewise did not distinguish between treatments. Adverse events led to discontinuation of 13 (IS%) patients from LTG and 18 ( 1 9%) from PHT. The adverse-event profile for LTG w.as dominated by skin rash (discontinuation of 10 (11.6%) patients compared with five (5.3%) from PHT] rather than central nervous system side effect sthenia, somnolence, and ataxia were each significantly inore frequent in the PHT group. The high rate of rash with LTG was probably due to the high starting dose and may be avoidable. A quality-of-life instrument. the SEALS inventory, favoured LTG. Patients taking PHT showed the biochemical changes expected of an eiizyrneinducing drug, whereas those taking LTG did not.Cotwlusiot~.~: LTG and PHT monotherapy were similarly effective against these seizure types in patients with newly diagnosed epilepsy. LTG was better tolerated, inore frequently causing rash. but with a lower incidence of central nervous system side effects.

show abstract

Section: Methodsmentioning

confidence: 99%

Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin

et al. 1999

View full text Add to dashboard Cite

show abstract

“…A patient-based assessment of AE related to use of AEDs was developed for inclusion in an HRQOL measure (31). The 20-item scale covers systemic and neurological problems similar to those included in the VA scales, with graded responses made by the patient.…”

Section: Scalesmentioning

confidence: 99%

Commission on Outcome Measurement in Epilepsy, 1994–1997: Final Report

et al. 1998

View full text Add to dashboard Cite

“…[5] Some adverse effects, especially those related to CNS toxicity, are particularly insidious in young children and in those with neurological comorbidities and psychiatric or behavioural problems. [6] A standardized adverse event questionnaire may be useful for monitoring adverse effects and optimizing AED therapy, [7] although data on subjective symptoms are hardly obtained from young children.…”

mentioning

confidence: 99%

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

et al. 2012

View full text Add to dashboard Cite

Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments

Cited by 75 publications

References 14 publications

Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin

Lamotrigine Monotherapy in Newly Diagnosed Untreated Epilepsy: A Double‐Blind Comparison with Phenytoin

Commission on Outcome Measurement in Epilepsy, 1994–1997: Final Report

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

Contact Info

Product

Resources

About